Hematologic complications of immune checkpoint inhibitors
Top Cited Papers
Open Access
- 23 June 2022
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 139 (25) , 3594-3604
Abstract
Immune checkpoint inhibitors are a class of antineoplastic therapies that unleash immune cells to kill malignant cells. There are currently 7 medications that have been approved by the US Food and Drug Administration for the treatment of 14 solid tumors and 2 hematologic malignancies. These medications commonly cause immune-related adverse effects as a result of overactive T lymphocytes, autoantibody production, and/or cytokine dysregulation. Hematologic toxicities are rare and of uncertain mechanism, and therefore management is often based on experiences with familiar conditions involving these perturbed immune responses, such as autoimmune hemolytic anemia, immune thrombocytopenia, and idiopathic aplastic anemia. Management is challenging because one must attend to the hematologic toxicity while simultaneously attending to the malignancy, with the imperative that effective cancer therapy be maintained or minimally interrupted if possible. The purpose of this review is to help clinicians by providing a clinical and pathophysiological framework in which to view these problems.Keywords
This publication has 66 references indexed in Scilit:
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin FailureJournal of Clinical Oncology, 2016
- Human IgG4: a structural perspectiveImmunological Reviews, 2015
- Adaptive Immune Resistance: How Cancer Protects from Immune AttackCancer Discovery, 2015
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated MelanomaNew England Journal of Medicine, 2015
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaNew England Journal of Medicine, 2015
- The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and bloodNature Immunology, 2012
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4Science, 2011
- The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopeniaBlood, 2011
- T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpuraNature Medicine, 2003
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995